T cell lymphomas are among the toughest blood cancers to treat. Immunotherapy, despite its success in many cancers, struggles ...
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive ...
Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma (PTCL) with 10% CD30 expression: Primary analysis results from the phase 2 SGN35-032 study. Safety and ...
Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...
The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...
When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...
T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results